PSMA PET/CT Versus mpMRI for the Detection of Clinically Significant Prostate Cancer: An Updated Overview

Area of Science:

• Urology
• Radiology
• Oncology

Background:

• Multiparametric MRI (mpMRI) is a standard for prostate cancer (PCa) diagnosis per EAU guidelines.
• Prostate-specific membrane antigen PET (PSMA-PET) is typically used for staging and recurrence detection in PCa.
• Emerging research investigates PSMA-PET's utility in primary diagnosis and detecting clinically significant PCa (csPCa).

Purpose of the Study:

• To provide an updated literature review on imaging modalities for detecting csPCa.
• To focus on the comparative performance of mpMRI and PSMA-PET in csPCa detection.
• To evaluate the evolving role of PSMA-PET in various clinical scenarios of PCa management.

Main Methods:

• Literature review of current studies on mpMRI and PSMA-PET for PCa detection.
• Analysis of comparative studies focusing on clinically significant PCa (csPCa).
• Synthesis of evidence regarding the diagnostic accuracy and clinical utility of both imaging techniques.

Main Results:

• mpMRI is established for primary diagnosis, while PSMA-PET excels in staging and recurrence.
• Studies suggest PSMA-PET may offer added value in primary diagnosis and identifying csPCa.
• Direct comparative data between mpMRI and PSMA-PET for csPCa detection is expanding.

Conclusions:

• Both mpMRI and PSMA-PET are crucial tools in prostate cancer management.
• PSMA-PET shows promise beyond its current indications, particularly for csPCa detection.
• Further research is needed to fully elucidate the comparative benefits and optimal integration of mpMRI and PSMA-PET.